Advanced Search


Study ID Status Title Patient Level Data
POP5108 Completed A repeated dose pharmacokinetic study in healthy volunteers to compare 1.5 mg of fondaparinux sodium in subjects with a low (35 to 50 kg) body weight (LBW) to 2.5 mg of fondaparinux sodium in subjects with standard (60 to 100 kg) body weight (SBW)
RA4104917 Completed A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing of GW274150 or 7.5mg prednisolone in RA subjects. Study Listed on
RES11070 Completed A randomised, double-blind, triple-dummy, placebo-controlled, five-way crossover study to investigate the bronchoprotective effects against methacholine challenge and the bronchodilatory effects of single doses of salmeterol (25, 50 and 200 µg) and salbutamol (200 µg) over a 24-hour period in atopic non-asthmatic subjects. Study Listed on
ROF102100 Completed A randomised, double blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole (CR) (1-24 mg) administered once daily for 12 weeks in subjects with fibromyalgia Study Listed on
ROP109087 Completed An open label, repeat dose, dose escalation study conducted in Parkinson's Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets. Study Listed on
ROR104836 Completed A parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs Syndrome. Study Listed on
ROX104805 Completed A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting from Ropinirole Immediate Release (IR) to Ropinirole Extended Release (XR) Formulation in Patients with Restless Legs Syndrome (RLS) Study Listed on
RRL103628 Completed An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628) Study Listed on
RRL103660 Completed A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients with Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep Study Listed on
S2W40024 Completed A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan 1mg TwiceDaily as Prophylactic Treatment for Menstrually-Associated Migraine. Study Listed on
S2W40027 Completed An open-label evaluation of the long-term safety of oral naratriptan 1mg twice daily as short-term prophylactic treatment for menstrually-associated migraine. Study Listed on
S3A40319 Completed A Phase IV, Multi-Center, Two-Arm, Single-Dose Pharmacokinetic Study of Intravenous ZOFRAN in Pediatric Surgical Patients from 1 Month to 24 Months of Age
S3A40320 Completed An Open-label, Multicenter, Study of the Safety and Antiemetic Effect of 0.15 mg/kg Intravenous Ondansetron Hydrochloride Administered for Three Doses to Pediatric Cancer Patients Aged 6 Months to 48 Months Who Are Receiving Moderately to Highly Emetogenic Chemotherapy
S3A40323 Completed A Randomized, Double-blind, Placebo-controlled, Multi-center Study of Intravenous Ondansetron Hydrochloride 0.1 mg/kg for the Prevention of Postoperative Emesis in Pediatric Surgical Subjects Ages 1 Month to 24 Months Who Are Undergoing Routine Surgery Under General Anesthesia.
SAM40008 Completed A Multicentre, Randomised, Double-Blind, Parallel Group Comparison of the Efficacy of SERETIDE* bd and Fluticasone Propionate bd (Both Via DISKUS*/ACCUHALER*, Inhaler) when Tapering the Inhaled Corticosteroid Dose in Asthmatic Adults Study Listed on
SAM40012 Completed A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate (SFC) 50/100mcg strength) bd via DISKUS/ACCUHALER inhaler, 2) fluticasone propionate 200mcg bd via DISKUS/ACCUHALER inhaler, 3) fluticasone propionate 100mcg bd via DISKUS/ACCUHALER inhaler in children aged 4- 11 years with asthma Study Listed on
SAM40027 Completed A Multicentre, stratified, randomised, double-blind, parallel-group, step-up comparison of the level of asthma control achieved with salmeterol/fluticasone propionate combination diskus (Accuhaler) dry powder inhaler compared with fluticasone propionate Diskus alone in adults and adolescents. Study Listed on
SAM40031 Completed A 13 month, randomised, double-blind, parallel-group comparison of the efficacy of Seretide and Flixotide(fluticasone propionate Accuhaler) when down-titrating the inhaled corticosteroid dose in asthmatic adults who have previously received SeretideTM 500/50 mg twice daily for at least 4 weeks. Study Listed on
SAM40036 Completed A 12-week multicentre, randomised, double-blind, double-dummy, parallel group study to compare the efficacy and tolerability of once daily salmeterol/fluticasone propionate combination (salm/FP) 50/100mcg at night via the DISKUS/ACCUHALER with once daily budesonide (BUD) 400mcg at night via a breath-actuated dry powder inhaler (BADPI) as initial maintenance therapy in mild-to-moderate asthmatic subjects Study Listed on
SAM40040 Completed A 24-week, randomsed, double dummy, double blind, parallel group study to compare the occurence of exacerbations between Seretide Diskus 50/250 bd and Symbicort BADPI (Turbuhaler) 4.5/160 two inhalations bd in subjects with moderate to severe asthma Study Listed on
SAM40042 Completed A double-blind, double-dummy, randomised, cross-over study to compare the bronchodilating action of Seretide Accuhaler 50/100mcg and Symbicort breath-actuated dry powder inhaler 6/200mcg in subjects with asthma after a single dose before and after 4 weeks of treatment Study Listed on
SAM40056 Completed Randomised, double-blind, double-dummy, 52-week, parallel group study of a standard dosing regimen with salmeterol/fluticasone propionate50/250 twice daily Diskus versus a symptom-driven, variable dosing regimen with formoterol/budesonide combination 4.5/160 in adult asthmatics Study Listed on
SAM40058 Completed A double-blind, randomised, parallel group study to evaluate the safety and tolerability of administering two inhalations twice daily of the salmeterol/fluticasone propionate combination (SERETIDE) in subjects with asthma over two weeks. Study Listed on
SAM40062 Completed A single-centre, single-dose, double-blind, double-dummy, placebo-controlled, randomised, three-way crossoverstudy to compare the duration of action of SERETIDE* DISKUS* 50/100mcg versus formoterol/budesonidecombination 4.5/160mcg Breath-Actuated Dry Powder Inhaler (BADPI) in subjects with asthma Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.